Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Eaton Corporation plc (ETN) Price & Performance

Citius Pharmaceuticals IncTrade
Eaton Corporation plcTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Eaton Corporation plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Eaton Corporation plc trades at $463.37 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 8636.7× Citius Pharmaceuticals Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRETN
Market Cap
$20.01M$172.82B
Sector
HealthTechnology
52-Week High
$1.82$459.29
52-Week Low
$0.48$315.82
Enterprise Value
$16.23M$193.45B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Eaton Corporation plc

Eaton Corporation (ETN) trades at $468.37, up 5.26% in 24 hours, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend with support at $456 and resistance at $470. Q2 2026 earnings beat expectations with EPS of $3.15 versus $3.07 estimated, and the company raised its full-year outlook, driven by robust demand in electrical and data center segments.

Outlook remains positive given raised guidance and AI-driven power infrastructure demand, but risks include premium valuation (P/E 45.31) and execution challenges. Analyst consensus is bullish with a $499.75 price target, though investors should monitor competitive pressures and macroeconomic conditions affecting industrial spending.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Eaton Corporation plc

Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.

Read more on ETN